This article was originally published in The Gray Sheet
Theratronics acquisition will become an operating division of the parent company's MDS Nordion business under the recent acquisition agreement ("The Gray Sheet" June 1, p. 4). MDS maintains that there is no product overlap between the firms in the distribution of cobalt-60 since MDS Nordion supplies low specific activity cobalt-60 to the industrial irradiation market for gamma sterilization and Theratronics supplies high specific activity cobalt-60 sources for radiotherapy equipment. In addition, MDS Nordion's 1995 licensing agreement was with Theragenics, not Theratronics
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.